With better understanding of endothelial progenitor cells (EPCs), many therapeutic approaches to cardiovascular diseases have been developed. This article will review novel research of EPCs in promoting angiogenesis, vasculogenesis, and endothelialization, as a design for future clinical treatment. Cell therapy has the potential to supply stem/progenitor cells and multiple angiogenic factors to the region of ischemia. The efficacy of EPC transplantation may be impaired by low survival rate, insufficient cell number, and impaired function in aging and diseases. Combination of EPCs or cells primed with growth factors or genetic modification may improve the therapeutic efficacy. The molecular mechanism involved in EPC repairing processes is essential. Thus, we have also addressed the molecular mechanism of mobilization, homing, and differentiation of EPCs. The potential of therapeutic neovascularization, angiogenic factor therapy, and cell transplantation have been elucidated. Based on past experience and actual knowledge, future strategies for EPC therapy will be proposed in order to fully exploit the potential of EPC transplantation with clinical relevance for cardiovascular disease applications.
INTRODUCTION
In response to ischemic injury, EPCs are mobilized from the bone marrow. The infusion or injection of stem or progenitor cells has been shown to improve neovasCell therapy is currently attracting growing attention as a potential issue of improving the prognosis of pacularization and heart function after ischemia in various experimental studies and clinical trials (46, 52, 106) . tients with cardiovascular diseases (22, 52, 77, 97, 113) . Cell-based therapy to stimulate postnatal vasculogenesis EPCs can migrate to the site of blood vessel injury to help repair the damage and to differentiate into mature or to repair the integrity is being evaluated for cardiovascular diseases with excess morbidity and mortality, endothelial cells (37). Therefore, it can be therapeutically useful for treating ischemic injury. Studies have including the ischemic heart disease, in-stent restenosis, pulmonary hypertension, and peripheral arterial occludescribed reduced EPC numbers in diabetic patients who suffered a stroke (115) . A report also indicated that EPC sive disease (3, 39, 79) . To date several clinical studies have suggested the potential efficacy of several different number correlated with the level of stromal derived factor-1 (SDF-1) from patients with the coronary disease or cell types (6, 67, 77, 79) . Endothelial progenitor cells (EPCs) have been studied as a novel tool to assess the severity ischemic cardiomyopathy (33). Because EPCs are involved in neovascularization, enhancing the number of cardiovascular disease and as a new strategy in regenerative medicine (21, 77, 113) .
and/or activity of EPCs could improve the recovery of patients who experience ischemic injury. They might body-coated stent have been evaluated as a replacement to currently available drug-eluting or bare metal stents also be useful as autologous vectors for delivering genes to sites of vascular growth in regenerating tissues (59). (63) . The treatment with G-CSF, which mobilizes EPCs from bone marrow, can safely improve the clinical outApplications associated with cardiovascular diseases depend on the functional activity of EPCs (39, 77, 115) .
comes of patients with atherosclerotic peripheral artery disease (PAD) (83) . Moreover, implantation of EPCs EPCs from type II diabetes patients exhibit impaired proliferation, adhesion, and reduced angiogenic potential and bone marrow cells may result in increase in atherosclerotic plaque size and composition in apolipoprotein in vitro (26). Similar functional alterations have been indicated in EPCs isolated from aged patients with coro-E knockout mice (30). Besides, the obvious therapeutical potential of blood-derived progenitor cells in panary artery disease or ischemic cardiomyopathy (35,47). However, controversial issues on EPC phenotypes, oritients indicates that the application is safe, feasible, and may improve both functional and clinical indices with gins, and functions of endothelial repair still exist. For example, the potential limitation for cell therapy is a low peripheral arterial occlusive disease and critical limb ischemia (48) . Additionally, the ability of G-CSF to mobirate of engraftment and persistence of cells in the ischemic tissue.
lize functional EPCs in patients with coronary artery disease has been tested in a clinical trail (1, 74, 104 ). The present review focuses on the role of EPCs in repairing the vessel wall during the development of carEvidence showed that the transplantation of EPCs resulted in a significant increase in myocardial viability diovascular disease. We address the recent developments in EPC functionality for cell therapy and the effiand perfusion (4, 23) . Alteration in progenitor cell proangiogenic function may participate to the hypertensionciency of EPCs on the maintenance of endothelial integrity, endothelialization, and angiogenesis from in induced impairment in postischemic revascularization (111) . When systemically applied, spleen-derived mouse vitro to in vivo study after cell transplantation. mononuclear cells (MNCs) and EPCs home to the site CLINICAL TRIALS OF EPC THERAPY of vascular injury, resulting in enhanced reendothelializ-
IN CARDIOVASCULAR DISEASES
ation associated with decreased neointima formation after angioplasty (101, 102) . Alternatively, the enhanced Much evidence has shown that EPCs may be a valuable tool for clinical health providers (25, 55, 80) . Imporregenerative activity of EPCs by human telomerase reverse transcriptase transfer will provide novel therapeutantly, EPC function and number now have been highly correlated with the risk of cardiovascular disease (7, 57) .
tical strategies for postnatal neovascularization in severe ischemic disease patients (65) . Indeed, ex vivo expanded A recent study showed that the level of circulating EPC expression level predicted the occurrence of cardiovasEPCs can incorporate into the foci of myocardial neovascularization and have a favorable impact on the prescular events and vascular tissue injury (2) . Interestingly, a study indicated that the increased number and funcervation of left ventricular function (45) . tionality of EPCs may be achieved by targeted pharma-THE TRANSPLANATION OF EPCs cological strategies alone (85) riosclerosis (28). Several studies have highlighted that the increase in the number of circulating progenitors, In addition, intramyocardial VEGF-A165 gene transfer followed by bone marrow stem cell mobilization with induced by cell transfusion or enhanced mobilization, can also enhance restoration and integrity of the endogranulocyte colony-stimulating factor (G-CSF) seemed to be safe in improving the homing of stem cells and thelial lining, suppress neointimal formation, and increase blood flow to ischemic sites (5,87). inducing angiogenesis in patients with severe chronic ischemic heart disease (76) .
In patients, the number of EPCs is poorly correlated with the severity of atherosclerosis (36). Indeed, in variStudies have also suggested that the implantation of endothelial progenitor cells could be safe and effective ous animal models, transplantation of bone marrow-derived progenitor cells could sufficiently rescue organ function for achievement of therapeutic angiogenesis for patients with limb ischemia (107). In an alternate study, percutaand enhance vascular repair and tissue regeneration (16,49,90 An important report indicated that the intravenous inopoietin-2 (94), and heme oxygenase-1 (HO-1) (58) that are well known to mobilize human stem cells have been fusion of spleen-derived mononuclear cells seemed to improve the endothelium-dependent vasodilatation in found to increase the number of EPCs in arterial remodeling during ischemic damage. An increase in the numatherosclerotic mice (101) . It is thus more convincing that progenitor cells play an important role in repairing ber of circulating progenitor cells, induced by cell transfusion or enhanced mobilization, can also enhance the the vascular injury (60, 102) . In addition, EPCs derived from spleen homogenates also enhanced reendothelializrestoration and integrity of the endothelial lining, suppress neointimal formation, and increase the blood flow ation and reduce neointima formation after induction of endothelial cell damage using the carotid artery animal to ischemic sites (8, 31, 72, 98) . However, the beneficial outcome of EPC infusion depends on the growth and model (102) . Besides, rapid repair of the endothelium with reduced activation of smooth muscle cells and neodifferentiation factors within the tissue, cell-to-cell interactions, and the degree of injury (75, 112) . intima formation has been found in vivo after the implantation of EPCs using a ballon injury model (68,105).
Experimental studies have provided novel options for improving survival and function by transduction of stem The transplantation of EPCs into mice after balloon injury could induce endothelial nitric oxide (eNOS) overor progenitor cells with prosurvival genes (e.g., Akt or telomerase) (18, 38, 78) . Pretreatment of cells with small expression and accelerate the endothelial repair (96) . In an alterative study, EPCs reduced the proinflammatory molecules, such as statins, p38 inhibitors, or endothelial nitric oxide synthase (eNOS) enhancers, has been used properties and the IL-10 expression in the atherosclerosis plaque site in mice model (19) .
to enhance cell homing, migration, and functional recovery after the induction of ischemia (18). Several studies The infusion of EPCs or isolated hematopoietic progenitor cells promotes neovascularization of ischemic have shown that the prosurvival phosphatidyl-inositol-3-kinase (PI3K)/Akt pathway may play an important role myocardium and improves the ventricular function after myocardial ischemia in both human and animal study in endothelial cells and EPCs (20, 114) . Thus, statins, VEGF, EPO, estrogen, and shear stress have also been (40, 62, 69) . In a canine model, circulating endothelial progenitor cells could be a substitute source of endothealso reported to modulate the PI3K/Akt pathway (20, 27, 41, 51, 86, 100) . Recently, the increased number of EPCs lial cells for endothelialization on small-diameter-vessel prostheses to ensure nonthrombogenicity (109) . A novel and enhanced neovascularization through an eNOSdependent pathway were also reported. The activity of hybrid cell-gene therapy based on the phagocytosing action of EPCs was explored as a new therapeutic strategy eNOS is essential for ischemic remodeling, and to mobilize EPCs and even modulate the neurogenesis in brain. for the treatment of pulmonary hypertension (66) . Alternatively, a possible role of SDF-1 in the homing of stem Besides, reports also addressed that eNOS improved angiogenesis and cerebral blood flow in the stroke animal cells to damage areas has been noted in the animal models of liver, limb, heart, and brain injury (42,64,95,108). model (13, 14) . Increased nitric oxide (NO) availability is required for the statin-induced mobilization of EPCs Overall, it seems that proper mobilization of EPCs may lead to the repair of vascular injury. The application of (73) . NO produced by eNOS also correlates with SDF-1 and the CXCR4 signaling pathway to induce the mobiendothelial progenitor cells on various cardiovascular diseases is summarized by Figure 1 .
lization and homing of EPCs (114).
Although the importance of SDF-1 in stem cell re-MECHANISM UNDERLYING cruitment to the injured tissue is well established, the THE THERAPEUTIC EFFECTS underlying mechanism of SDF-1 in ischemic tissue still OF ENDOTHELIAL PROGENITOR CELLS needs to be elucidated. Furthermore, SDF-1 gene expression is regulated by the transcription factor hypoxicAs highlighted by several reports, the functional repair properties of EPCs derived from different sources, inducible factor-1 (HIF-1) in endothelial cells, resulting in selective in vivo expression of SDF-1 in ischemic tisincluding bone marrow and non-bone marrow organs such as the spleen, may vary with the maturation state sue (44). SDF-1 is the only chemokine family member known to be regulated by HIF-1 (10). It seems reasonof the cells (112) . Thus, understanding the molecular mechanisms involved in EPC-repairing processes is esable that HIF-1-regulated SDF-1 expression may be important in a number of regenerative pathways. Thus, exsential. Here, we will review the mechanism for mobili- pression of HIF-1 activity may be a useful approach to cules in the recruitment of EPCs to ischemic tissue. The knowledge may provide novel opportunities for clinical improve the regenerative potential after ischemic injury (44). Integrins are crucial transmembrane molecules that cardiovascular disease applications. A summary of the possible mechanisms between EPCs and cardiovascular mediate cell adhesion, migration, and the homing of progenitor cells such as EPCs to ischemic tissue, possibly disease is shown in Figure 2 . through the enhanced angiogenesis by homing stem cells FUTURE EXPLORATION (54) . The β2-integrins are involved in the homing of EPCs to the site of ischemia and are essential for their Cell-based transplantation strategies have the potential to become a major therapeutic advance for cardioneovascularization capacity in vivo (11). The activation of β2-integrin on EPCs has been shown to significantly vascular disease. There are still controversial issues regarding the active potency of EPCs for proliferation, improve the neovascularization capacity in vivo in a model of hindlimb ischemia (9) . Whether integrins play differentiation, and migration in vitro, therapeutic neovascularization and reendothelialization in vivo of the an important role for the mechanism of repair in cardiovascular disease remains to be determined in the future.
EPC-based treatments. Although available clinical studies of EPC transplantation show beneficial results in Besides, further studies are still required to elucidate whether there is a synergism between adhesion moleterms of improvement in cardiovascular disease and re-modeling after myocardial infarction (91) , these studies the clinical trail of EPCs. EPCs are relatively rare cells, and expansion of sufficient number of a definite subpopstill encounter some difficult issues that need to be solved in the future.
ulation from peripheral blood is hardly possible. Additionally, the therapeutic implantation is associated with Clear characterization of the specific subpopulation of stem/bone marrow cells that have the most beneficial a change in phenotype and differentiation and the risk of cell biology, and may need other activation or stimuproperties is important for vascular repair (12,29,32) . Thus, it is also necessary to develop a safe protocol and hope lation (50, 99) . Besides, the ability and functional properties of EPCs in aging adults are really limited, especially to isolate sufficient numbers of EPCs that can continuously maintain their angiogenic potential and be used in those with cardiovascular disease where a further reduction of EPCs was shown (82, 92) . to treat patients in clinical trails with damaged vascular tissues. Ideally, a specific cell population or combination CONCLUSION needs to be accurately determined. It is important to note that most preclinical and clinical studies testing the therStem cell therapy is feasible, moderately effective, and does not expose patients to high risk. The therapeuapeutic effects of EPCs were based on introducing either whole bone marrow cells or a crude bone marrow cell tic effects of EPCs are well performed in several studies, but there are things remaining obscure. A combined cell population containing EPCs, hematopoietic cells, and irrelevant pluripotent cells, with some animal experiments therapy comprising EPCs is also a promising option, but issues regarding the types of patients, the types of used using purified "EPCs," such as CD34
+ hematopoietic stem cells (HSCs) (34, 84) . cells, and the therapeutic outcomes all complicate the wide use of cell therapy. There is also the necessity of Alternatively, a major problem was also observed in Figure 2 . Possible molecular mechanism between EPCs and cardiovascular diseases. VEGF, vascular endothelial growth factor; G-CSF, granulocyte colony-stimulating factor; FGF, fibroblast growth factor; PIGF, placenta growth factor; HGF, hepatocyte growth factor; SDF-2, stromal derived factor 1; IL-1β, interleukin-1β; IL-3, -6, -8, interleukin-3, -6, -8; TNF-α, tumor necrosis factor-α; eNOS, endothelia nitric oxide synthase; NO, nitric oxide; CRP, C-reactive protein; LDL, low density lipoprotein; EPO, eryothropietin; HIF-1, hypoxia inducible factor. 
